Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380681935> ?p ?o ?g. }
- W4380681935 endingPage "3172" @default.
- W4380681935 startingPage "3172" @default.
- W4380681935 abstract "Immune checkpoint inhibitor-based therapies represent the current standard of care in the first-line treatment of advanced renal cell carcinoma. Despite a clear benefit in survival outcomes, a considerable proportion of patients experience disease progression; prospective data about second-line therapy after first-line treatment with immune checkpoint inhibitors are limited to small phase II studies. As with other solid tumors (such as melanoma and non-small cell lung cancer), preliminary data about the clinical efficacy of rechallenge of immunotherapy (alone or in combination with other drugs) in renal cell carcinoma are beginning to emerge. Nevertheless, the role of rechallenge in immunotherapy in this setting of disease remains unclear and cannot be considered a standard of care; currently some randomized trials are exploring this approach in patients with metastatic renal cell carcinoma. The aim of our review is to summarize main evidence available in the literature concerning immunotherapy rechallenge in renal carcinoma, especially focusing on biological rationale of resistance to immune checkpoint inhibitors, on the published data of clinical efficacy and on future perspectives." @default.
- W4380681935 created "2023-06-15" @default.
- W4380681935 creator A5009256008 @default.
- W4380681935 creator A5018474702 @default.
- W4380681935 creator A5029935476 @default.
- W4380681935 creator A5038300856 @default.
- W4380681935 creator A5047062088 @default.
- W4380681935 creator A5051858263 @default.
- W4380681935 creator A5054927100 @default.
- W4380681935 creator A5062562691 @default.
- W4380681935 creator A5088352377 @default.
- W4380681935 creator A5092170458 @default.
- W4380681935 date "2023-06-13" @default.
- W4380681935 modified "2023-09-27" @default.
- W4380681935 title "Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma: Current Evidence and Future Directions" @default.
- W4380681935 cites W1968594028 @default.
- W4380681935 cites W1969963445 @default.
- W4380681935 cites W2011458181 @default.
- W4380681935 cites W2026861011 @default.
- W4380681935 cites W2050248869 @default.
- W4380681935 cites W2067969350 @default.
- W4380681935 cites W2078844752 @default.
- W4380681935 cites W2080886891 @default.
- W4380681935 cites W2082739830 @default.
- W4380681935 cites W2083676244 @default.
- W4380681935 cites W2083870593 @default.
- W4380681935 cites W2100945326 @default.
- W4380681935 cites W2102532180 @default.
- W4380681935 cites W2118964372 @default.
- W4380681935 cites W2122037714 @default.
- W4380681935 cites W2131783235 @default.
- W4380681935 cites W2144952279 @default.
- W4380681935 cites W2157076786 @default.
- W4380681935 cites W2159803625 @default.
- W4380681935 cites W2201379305 @default.
- W4380681935 cites W2237254160 @default.
- W4380681935 cites W2340861895 @default.
- W4380681935 cites W2342868230 @default.
- W4380681935 cites W2415950182 @default.
- W4380681935 cites W2588686192 @default.
- W4380681935 cites W2617316779 @default.
- W4380681935 cites W2761575992 @default.
- W4380681935 cites W2765417948 @default.
- W4380681935 cites W2790729376 @default.
- W4380681935 cites W2805302875 @default.
- W4380681935 cites W2898830231 @default.
- W4380681935 cites W2898915459 @default.
- W4380681935 cites W2965696875 @default.
- W4380681935 cites W2988644538 @default.
- W4380681935 cites W2991986029 @default.
- W4380681935 cites W3018979351 @default.
- W4380681935 cites W3028977302 @default.
- W4380681935 cites W3029478055 @default.
- W4380681935 cites W3042347895 @default.
- W4380681935 cites W3089461485 @default.
- W4380681935 cites W3093923068 @default.
- W4380681935 cites W3095969449 @default.
- W4380681935 cites W3107453141 @default.
- W4380681935 cites W3131063362 @default.
- W4380681935 cites W3133762486 @default.
- W4380681935 cites W3134509668 @default.
- W4380681935 cites W3134949580 @default.
- W4380681935 cites W3135222010 @default.
- W4380681935 cites W3167370803 @default.
- W4380681935 cites W3171824834 @default.
- W4380681935 cites W3172306975 @default.
- W4380681935 cites W3203988497 @default.
- W4380681935 cites W3204552453 @default.
- W4380681935 cites W4210882774 @default.
- W4380681935 cites W4213022323 @default.
- W4380681935 cites W4220685687 @default.
- W4380681935 cites W4223494321 @default.
- W4380681935 cites W4223622882 @default.
- W4380681935 cites W4225790409 @default.
- W4380681935 cites W4226082711 @default.
- W4380681935 cites W4281645962 @default.
- W4380681935 cites W4295837188 @default.
- W4380681935 cites W4308026783 @default.
- W4380681935 cites W4310368499 @default.
- W4380681935 cites W4311115690 @default.
- W4380681935 cites W4324136540 @default.
- W4380681935 doi "https://doi.org/10.3390/cancers15123172" @default.
- W4380681935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37370782" @default.
- W4380681935 hasPublicationYear "2023" @default.
- W4380681935 type Work @default.
- W4380681935 citedByCount "0" @default.
- W4380681935 crossrefType "journal-article" @default.
- W4380681935 hasAuthorship W4380681935A5009256008 @default.
- W4380681935 hasAuthorship W4380681935A5018474702 @default.
- W4380681935 hasAuthorship W4380681935A5029935476 @default.
- W4380681935 hasAuthorship W4380681935A5038300856 @default.
- W4380681935 hasAuthorship W4380681935A5047062088 @default.
- W4380681935 hasAuthorship W4380681935A5051858263 @default.
- W4380681935 hasAuthorship W4380681935A5054927100 @default.
- W4380681935 hasAuthorship W4380681935A5062562691 @default.
- W4380681935 hasAuthorship W4380681935A5088352377 @default.
- W4380681935 hasAuthorship W4380681935A5092170458 @default.
- W4380681935 hasBestOaLocation W43806819351 @default.